Predicting liver injury in paracetamol overdose patients

Predicting liver injury in paracetamol overdose patients
The Liverpool team identified proteins and a strand of ribonucleic acid that may help develop a blood-based test to predict risk of liver injury.

Scientists at the University of Liverpool have identified molecules in the blood that could help predict the risk of a patient developing liver injury eight hours after a paracetamol overdose.

Paracetamol overdose is one of the most frequent cases of hospital admissions, accounting for approximately 90,000 hospital attendances per year in the UK and almost 47,000 bed days in England alone.  Overdose of the drug can result in liver damage, and in severe cases death.

Measuring biomarkers

The Liverpool team, in collaboration with the Royal Infirmary Edinburgh, the National Poisons Information Service, and Novartis, have identified proteins and a strand of ribonucleic acid (RNA) that may help in the future development of a blood-based test at hospitals to predict a patient's risk of .

These molecules, or biomarkers, are found in the liver, but when the die following paracetamol overdose, they spill out into the blood where scientists can measure them to give an indication of the level of injury to the liver.

Researchers, based at the University's Medical Research Council's (MRC) Centre for Drug Safety Science, showed that the biomarkers were more sensitive and accurate compared to current clinical methods and could predict the likelihood of eight hours after paracetamol overdose, a point at which indicators used today are ineffective.

Dr Dan Antoine, from the Centre for Science, said: "Clinicians work hard to treat paracetamol overdose patients as quickly as possible, but it is difficult to get the correct measure of treatment without a highly sensitive test that can predict the risk of the patient developing .

"The outcome of our study shows that it could be possible to develop a new test based on biomarkers in the blood, to determine which patients are at high risk of acute liver injury and which are not.  Identifying patients in this way will make a significant impact on clinical practice, reducing the number of and the length of time patients are treated with antidote."

add to favorites email to friend print save as pdf

Related Stories

Model predicts death due to acetaminophen overdose

Feb 24, 2012

(HealthDay) -- Model for Acetaminophen-induced Liver Damage (MALD), a mathematical model that utilizes commonly obtained laboratory values, including overdose amount and time elapsed since overdose, is effective ...

Recommended for you

Tough-to-abuse formulation of oxycodone approved

5 minutes ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

18 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

22 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

23 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments